Neuropsychopharmacology Reports最新文献

{"title":"Association between psychological distress and schizotypy in adults: A cross-sectional study.","authors":"Hiroyuki Uchida, Sae Ohki, Chiaki Kuroiwa, Kenji Tsuchiya, Senichiro Kikuchi, Kazuki Hirao","doi":"10.1002/npr2.12511","DOIUrl":"10.1002/npr2.12511","url":null,"abstract":"<p><strong>Background: </strong>Schizotypy refers to a personality type characterized by behavioral and cognitive abnormalities similar in nature but less severe than those of schizophrenia. Schizotypy often progresses to schizophrenia, so identifying risk factors may facilitate early schizophrenia diagnosis and improve treatment. Psychological distress may be associated with schizotypy, highlighting its importance. However, the link between psychological distress and schizotypy remains unclear.</p><p><strong>Methods: </strong>This cross-sectional study examined the relationship between schizotypy and psychological distress in a Japanese adult population using internet-based questionnaires. Schizotypy was assessed using the Schizotypal Personality Questionnaire-Brief and psychological distress was measured using the Kessler Screening Scale for Psychological Distress. Multivariate logistic regression analysis was used to assess the relationship between psychological distress and schizotypy after adjusting for numerous potential confounding variables.</p><p><strong>Results: </strong>Among 6632 participants, 225 were classified with schizotypy (3.39%, 89 females [39.6%]). Multivariate logistic regression analysis adjusting for confounding factors revealed that participants with psychological distress were significantly more likely to exhibit signs of schizotypy than those without psychological distress (adjusted odd ratio, 2.91; 95% confidence interval, 1.85-4.59).</p><p><strong>Conclusions: </strong>The emergence of schizotypy in adults is strongly associated with psychological distress. This finding emphasizes the need for physicians to carefully, thoroughly, and routinely assess psychological distress in adults. Longitudinal studies are warranted to investigate the causal relationship between schizotypy and psychological distress.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":" ","pages":"e12511"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11772104/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142896339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The association between benzodiazepine prescriptions and the risk of laxative use in schizophrenia treatment.","authors":"Shinichiro Ochi, Takashi Tsuboi, Naomi Hasegawa, Hikaru Hori, Kayo Ichihashi, Yayoi Imamura, Tsuyoshi Okada, Fumitoshi Kodaka, Yoshitaka Saito, Jun-Ichi Iga, Toshiaki Onitsuka, Kiyokazu Atake, Shu-Ichi Ueno, Ryota Hashimoto, Norio Yasui-Furukori","doi":"10.1002/npr2.12499","DOIUrl":"10.1002/npr2.12499","url":null,"abstract":"<p><strong>Aim: </strong>Constipation is one of the most common adverse effects in schizophrenia treatment, and it can sometimes cause severe gastrointestinal disease. However, the results of association studies between constipation and psychotropic medications in patients with schizophrenia are inconsistent. Therefore, we investigated the characteristics of psychotropic and laxative prescriptions at discharge in patients with schizophrenia to clarify the association between psychotropics and constipation.</p><p><strong>Methods: </strong>We analyzed the data of 139 patients with schizophrenia with or without laxative prescriptions at discharge from eight institutions in 2020.</p><p><strong>Results: </strong>Sixty-two patients were prescribed laxatives at discharge. The prescription of benzodiazepines in the laxative use group (66.1%) was significantly higher than that in the non-laxative use group (39.0%) (p = 1.4 × 10^-3), and the mean number of benzodiazepines in the laxative use group (1.2 ± 1.1/day) was significantly higher than that in the non-laxative use group (0.7 ± 0.9/day) (p = 2.6 × 10^-3). Multivariate logistic regression analyses revealed that benzodiazepine prescriptions were significantly associated with laxative usage (odds ratio, 3.059; 95% confidence interval, 1.523-6.144; p = 2.0 × 10^-3).</p><p><strong>Conclusion: </strong>Benzodiazepines may be associated with constipation in patients with schizophrenia. Therefore, clinicians should be cautious when prescribing benzodiazepines for the treatment of schizophrenia.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":" ","pages":"e12499"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11666345/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142605585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proposal for a Novel Classification of Patients With Enlarged Ventricles and Cognitive Impairment Based on Data-Driven Analysis of Neuroimaging Results in Patients With Psychiatric Disorders.","authors":"Yuka Yasuda, Satsuki Ito, Junya Matsumoto, Naohiro Okada, Toshiaki Onitsuka, Masashi Ikeda, Itaru Kushima, Chika Sumiyoshi, Masaki Fukunaga, Kiyotaka Nemoto, Kenichiro Miura, Naoki Hashimoto, Kazutaka Ohi, Tsutomu Takahashi, Daiki Sasabayashi, Michihiko Koeda, Hidenaga Yamamori, Michiko Fujimoto, Harumasa Takano, Naomi Hasegawa, Hisashi Narita, Maeri Yamamoto, Khin Khin Tha, Masataka Kikuchi, Toshiharu Kamishikiryo, Eri Itai, Yoshiro Okubo, Amane Tateno, Motoaki Nakamura, Manabu Kubota, Hiroyuki Igarashi, Yoji Hirano, Go Okada, Jun Miyata, Shusuke Numata, Osamu Abe, Reiji Yoshimura, Shin Nakagawa, Hidenori Yamasue, Norio Ozaki, Kiyoto Kasai, Ryota Hashimoto","doi":"10.1002/npr2.70010","DOIUrl":"10.1002/npr2.70010","url":null,"abstract":"<p><p>One of the challenges in diagnosing psychiatric disorders is that the results of biological and neuroscience research are not reflected in the diagnostic criteria. Thus, data-driven analyses incorporating biological and cross-disease perspectives, regardless of the diagnostic category, have recently been proposed. A data-driven clustering study based on subcortical volumes in 5604 subjects classified into four brain biotypes associated with cognitive/social functioning. Among the four brain biotypes identified in controls and patients with schizophrenia, bipolar disorder, major depressive disorder, autism spectrum disorder, and other psychiatric disorders, we further analyzed the brain biotype 1 subjects, those with an extremely small limbic region, for clinical utility. We found that the representative feature of brain biotype 1 is enlarged lateral ventricles. An enlarged ventricle, defined by an average z-score of left and right lateral ventricle volumes > 3, had a sensitivity of 99.1% and a specificity of 98.1% for discriminating brain biotype 1. However, the presence of an enlarged ventricle was not sufficient to classify patient subgroups, as 1% of the controls also had enlarged ventricles. Reclassification of patients with enlarged ventricles according to cognitive impairment resulted in a stratified subgroup that included patients with a high proportion of schizophrenia diagnoses, electroencephalography abnormalities, and rare pathological genetic copy number variations. Data-driven clustering analysis of neuroimaging data revealed subgroups with enlarged ventricles and cognitive impairment. This subgroup could be a new diagnostic candidate for psychiatric disorders. This concept and strategy may be useful for identifying biologically defined psychiatric disorders in the future.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"45 1","pages":"e70010"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11864853/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143516263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"NSW cannabis medicines advisory service retrospective enquiry analysis to inform clinical guidance resource development.","authors":"Myfanwy Graham, Edward Eden, Kelsey Maddison, Luise Lago, Samuel Allingham, Catherine J Lucas, Jennifer Schneider, Jennifer H Martin","doi":"10.1002/npr2.12498","DOIUrl":"10.1002/npr2.12498","url":null,"abstract":"<p><strong>Background: </strong>An innovative New South Wales government funded statewide Cannabis Medicines Advisory Service (CMAS) operated between January 2018 and June 2022. The service provided comprehensive patient-specific and evidence-based information to support health professionals in prescribing and patient care decisions. This study aimed to describe real-world data collected by CMAS.</p><p><strong>Methods: </strong>A sub-set of de-identified, patient-specific enquiries collected between January 2021 and June 2022 (n = 123/567; 21.7%) were analyzed using R version 4.2.1. Diagnosis, indication, and comorbidities were coded using Medical Dictionary for Regulatory Activities (MedDRA) terminology.</p><p><strong>Results: </strong>Most patient-specific enquiries from medical practitioners were from general practitioners (n = 103/123; 83.7%). Female (n = 53/123; 43.1%) and male (n = 59/123; 48.0%) patients were similarly represented. Sex was not specified for 8.9% (n = 11/123) of patients. The mean age of patients was 52.1 years (range <10-90). The most common three diagnoses were osteoarthritis, anxiety, and chronic pain. Indications that were most frequently reported included chronic pain, anxiety, back pain, non-neuropathic pain, and insomnia. Comedications were most commonly non-opioid and opioid analgesics and antidepressants. Most practitioners were considering prescribing a cannabidiol (CBD) product for their patient. Cannabinoid composition selection guidance provided by CMAS was predominantly (delta-9-tetrahydrocannabinol) THC:CBD ~1:1, followed by CBD-only products. CMAS was contacted by health professionals regarding the management of potential adverse events for five patients.</p><p><strong>Conclusion: </strong>The findings of this study shed light on the information medical practitioners were seeking to inform their clinical decision-making about medical cannabis and can inform the development of clinical guidance resources.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":" ","pages":"e12498"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11660764/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142648479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of short-term exposure to moderate amounts of alcohol on brain volume.","authors":"Sakiko Tsugawa, Fumihiko Ueno, Mutsuki Sakuma, Hideaki Tani, Ryo Ochi, Ariel Graff-Guerrero, Yoshihiro Noda, Hiroyuki Uchida, Masaru Mimura, Shunji Oshima, Sachio Matsushita, Shinichiro Nakajima","doi":"10.1002/npr2.12500","DOIUrl":"10.1002/npr2.12500","url":null,"abstract":"<p><strong>Aim: </strong>Although numerous studies have reported that chronic alcohol consumption causes brain volume reduction and cerebrospinal fluid volume increase, few studies have examined the acute effects of alcohol on brain structure. This study aims to investigate the short-term brain volume changes following alcohol administration.</p><p><strong>Methods: </strong>Moderate doses of alcohol were administered intravenously to 18 healthy volunteers for a total of 90 min to achieve a blood alcohol concentration of 0.5 mg/mL. An alcohol clamp method combined with physiologically based pharmacokinetic modeling was used to achieve fine control over blood alcohol concentration. T1 images with 3T MRI were scanned at three time points: baseline, 0 min, and 90 min after the end of alcohol administration. Cortical, subcortical, and ventricular volumes were computed after segmentation with FreeSurfer. Repeated measures analysis of variance was used to evaluate longitudinal changes in brain volume at 96 regions.</p><p><strong>Results: </strong>Acute alcohol administration increased bilateral lateral ventricular volumes, which lasted until 90 min after the end of alcohol injection. On the other hand, the volumes of total gray matter, left precentral cortex, left caudal middle frontal cortex, and left superior frontal cortex decreased after alcohol administration, but these changes disappeared 90 min after the end of alcohol administration.</p><p><strong>Conclusion: </strong>Acute injection of moderate doses of alcohol may enlarge ventricle volumes and reduce gray matter volumes. The transient volume changes caused by acute administration of alcohol may be related to changes in CSF flow and water content of brain tissue, which warrants further study.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":" ","pages":"e12500"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11772103/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142818672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Orexin concentrations and diurnal variation in the cerebrospinal fluid of intensive care unit patients undergoing aortic surgery with spinal drainage.","authors":"Seiya Nishiyama, Akiko Sekine, Tomoyuki Masuyama, Kanae Nagatomo, Takashi Kanbayashi, Masamitsu Sanui","doi":"10.1002/npr2.12504","DOIUrl":"10.1002/npr2.12504","url":null,"abstract":"<p><strong>Background: </strong>Cerebrospinal fluid (CSF) levels of orexin show a cyclic diurnal variation in healthy subjects, which is diminished in patients with certain diseases. However, possible circadian variations in orexin levels in critically ill patients remain unknown. In this study, we evaluated the orexin concentrations in the CSF and their diurnal variation in patients undergoing thoracic aortic aneurysm repair with lumbar intrathecal catheterization for CSF drainage after non-neurosurgery.</p><p><strong>Methods: </strong>Eligible patients with a lumbar intrathecal catheter placed for CSF drainage following aortic surgery at a single-center ICU between September 2019 and February 2020 were included. Catheters were placed before anesthesia induction, and CSF was collected at the time of catheter placement, ICU admission, and daily at 6:00, 12:00, 18:00, and 24:00 until the catheter was removed or for up to 5 days after admission to the ICU.</p><p><strong>Results: </strong>Three patients (Patients A, B, and C) who underwent thoracic aortic aneurysm repair were included. Patients B and C received sedatives or hypnotics during the orexin measurement period. The baseline orexin levels for Patients A, B, and C were 219.9, 312.3, and 403.8 pg/mL, while the mean orexin levels were 319.4 ± 82.6, 372.4 ± 56.0, and 306.3 ± 48.3 pg/mL, respectively. For all three patients, orexin levels showed diurnal variations, but no consistent periodic changes.</p><p><strong>Conclusion: </strong>CSF orexin concentrations for patients undergoing thoracic aortic aneurysm repair in the ICU were within the reported range compared to those of previously reported healthy subjects; however, consistent periodic diurnal variations were not observed.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":" ","pages":"e12504"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11666344/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142624876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current status and features of antipsychotic prescriptions in Japanese forensic psychiatric wards based on a forensic inpatient database.","authors":"Koji Takeda, Hiroko Kashiwagi, Keisuke Takanobu, Ryotaro Kubota, Ryo Naoe, Yuji Yamada, Junko Koike, Toshiaki Kono, Yuki Kako, Naotsugu Hirabayasi","doi":"10.1002/npr2.12505","DOIUrl":"10.1002/npr2.12505","url":null,"abstract":"<p><strong>Aim: </strong>Psychopharmacotherapy plays an important role in the treatment of mentally disordered offenders (MDOs) with schizophrenia spectrum disorders. However, there have been few large-scale reports from multiple forensic psychiatric wards. This study aimed to clarify the current state of antipsychotic medications for MDOs with schizophrenia spectrum disorders in Japanese forensic psychiatric wards.</p><p><strong>Methods: </strong>Medical information, including age, sex, psychiatric diagnosis, index offense, seclusion or restraint experience during hospitalization, and medication for patients discharged from 32 forensic wards nationwide between September 1, 2019 and December 31, 2021 was provided by the Database Scientific Utilization Project of Japanese forensic psychiatric wards. We analyzed the data of MDOs with schizophrenia spectrum disorders who were prescribed psychotropic medications at the time of discharge, especially focusing on comparing differences between the three groups (clozapine, long-acting injection (LAI), and other medications).</p><p><strong>Results: </strong>A total of 362 MDOs with schizophrenia spectrum disorders were prescribed psychotropic medications at discharge. The prescription rates of clozapine and LAI were 23.2% and 24.9%, respectively. Additionally, the rate of antipsychotic polypharmacy was 37.8%. Among the three groups, the clozapine group had the highest rate of seclusion experience (46.4%), a long mean length of hospitalization (1758 days), and the lowest rate of antipsychotic polypharmacy (4.8%). Olanzapine was the most commonly prescribed antipsychotic medication.</p><p><strong>Conclusion: </strong>This study revealed the current state of antipsychotic medications for MDOs admitted to forensic psychiatric wards in Japan. Future studies are needed to clarify the relevance of antipsychotic medications in the prognosis of MDOs.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":" ","pages":"e12505"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11660762/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142731163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of 3,4-methylenedioxymethamphetamine on neural activity in the nucleus accumbens of male mice engaged in social behavior.","authors":"Naoya Nishitani, Yuki Sasaki, Katsuyuki Kaneda","doi":"10.1002/npr2.12510","DOIUrl":"10.1002/npr2.12510","url":null,"abstract":"<p><p>3,4-methylenedioxymethamphetamine (MDMA), a commonly abused recreational drug, induces prosocial effects such as increased sociability and empathy. The nucleus accumbens (NAc) has been suggested to play a crucial role in these MDMA-mediated prosocial effects. However, the relationship between social behavior and NAc neural activity, and the effects of MDMA on this relationship, remain unknown. In this study, we measured NAc neural activity using fiber photometry and classified the behaviors of mice at times of transient increases in NAc neural activity during the social approach test (SAT). We found that NAc neural activity transiently increased at the onset of turning toward and sniffing novel mice during the SAT, although the frequency of turning was relatively low. We then examined the effects of MDMA on behavior and NAc neural activity and found that MDMA decreased the duration of sniffing per bout but did not alter NAc neural activity at the onset of turning toward or sniffing novel mice. These results suggest that MDMA does not affect the transient increase in NAc neural activity at the onset of social behaviors.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":" ","pages":"e12510"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11666336/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142770750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of lemborexant in subjects with insomnia disorder receiving medications for depression or anxiety symptoms.","authors":"Andrew Krystal, Pierre Blier, Larry Culpepper, Andrew A Nierenberg, Yoshikazu Takaesu, Naoki Kubota, Margaret Moline, Manoj Malhotra, Kate Pinner, Jane Yardley","doi":"10.1002/npr2.12509","DOIUrl":"10.1002/npr2.12509","url":null,"abstract":"<p><strong>Aim: </strong>Individuals with insomnia frequently have comorbid depression or anxiety. This study sought to provide a preliminary indication of the effects of lemborexant (LEM) in subjects treated for mild depression/anxiety symptoms.</p><p><strong>Methods: </strong>E2006-G000-303 (NCT02952820; EudraCT 2015-001463-39; SUNRISE-2) was a 12-month, phase 3, randomized, placebo-controlled, double-blind study where subjects with insomnia disorder were randomized (1:1:1) to placebo, LEM 5 mg (LEM5), or LEM 10 mg (LEM10) for 6 months. During the second 6 months (not reported), placebo-treated subjects were re-randomized to LEM5 or LEM10. In this post hoc analysis, changes from baseline (CFB) in subject-reported (subjective) sleep onset latency (sSOL), sleep efficiency (sSE), wake after sleep onset (sWASO), total sleep time (sTST), Fatigue Severity Scale, and Insomnia Severity Index were evaluated in subjects treated with medications for symptoms of depression/anxiety (subpopulation).</p><p><strong>Results: </strong>Of 949 randomized subjects, 61 treated with medications for symptoms of depression/anxiety were included. In the subpopulation, CFB comparing LEM with placebo were generally smaller than the overall population due to a larger placebo response in the subpopulation. However, the magnitudes of CFB within the active treatment groups for sSOL, sWASO, sTST, and sSE were similar between the subpopulation and the overall population. No new safety signals were observed in the subpopulation.</p><p><strong>Conclusion: </strong>LEM treatment benefited subjects with insomnia treated with medications for depression/anxiety symptoms, with no new safety signals. A greater placebo response in the subpopulation than in the overall population decreased the drug versus placebo effect size for LEM, as has been reported for other insomnia medications.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":" ","pages":"e12509"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11666340/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142780488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Guideline for pharmacological treatment of schizophrenia 2022.","authors":"","doi":"10.1002/npr2.12497","DOIUrl":"10.1002/npr2.12497","url":null,"abstract":"","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":" ","pages":"e12497"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11666347/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142716381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}